New Regenerative Approach for Dermal Renovation (Karisma)

NCT ID: NCT06152718

Last Updated: 2023-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-01

Study Completion Date

2024-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose/Objectives of the Study: Regenerative medicine, as well as aesthetic plastic surgery and dermatology field persistently seeks innovative, minimally invasive interventions to enhance skin quality and mitigate signs of aging. This study evaluates the regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen, to verify its ability, in a specific formulation (contained within a matrix of hyaluronic acid and carboxymethylcellulose), to induce dermal stimulation in both scar outcomes and regenerative medicine applied to skin aging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Population (including any inclusion/exclusion criteria): : A total of 100 patients, aged between 25 and 70 years of both sexes, subdivided into 3 demographically similar subgroups, will be assessed in this exploratory study. The intervention entailed the administration of the single-strand alpha 1 collagen - hyaluronic acid soft filler, with subsequent evaluations employing the Antera 3D® skin scanner and two multiple choice questionnaires, FACE-Q and Global Aesthetic Improvement Scale (GAIS) to obtain objective data and subjective evaluations recorded by patients. All patients must be in good general health. not affected by oncological, rheumatological, chronic inflammatory diseases (including dermatitis, psoriasis, etc.). patients should not take systemic drugs during the course of the aforementioned study. The sample size of 100 patients is in line with studies already carried out in this field, in order to obtain adequate statistical power, also in anticipation of a physiological drop out of some patients. Parametric and non-parametric tests will be used to test the results to assess the significance of discrete and continuous numerical variables, as well as descriptive statistics for all patient groups.

Within the scope of this project, the investigators plan to recruit four cohorts of subjects:

1. smokers (30 subjects)
2. non-smokers (30 subjects)
3. subjects affected by acne scars (40)

All patients must be in general good health, not affected by oncological, rheumatological, allergic, chronic inflammatory diseases (including dermatitis, psoriasis, etc.). Patients should not have metabolic or cardiovascular diseases, should not have received other injections of hyaluronic acid or similar substances for at least 6 months before the start of treatment, and should not take systemic drugs during the study.

The primary endpoints will be those to evaluate the subjective changes in texture, hydration, compactness, brightness, and quality of skin roughness through the administration of multiple-choice tests already validated by numerous scientific studies (Global Aesthetic Improvement Scale GAIS; FACE-Q Age Appearance Appraisal) and objective changes through non-invasive measurements, such as dermal thickness by high-frequency ultrasound; the depth of wrinkles, amount of melanin and hemoglobin through 3D Antera Scanner, to assess the regenerative capabilities of the medical device in patients affected by acne scars, in the atrophic and dystrophic skin alterations of the body, as well as in the photo and chronoaging of the skin of the face, neck, and décolleté in smoking and non-smoking patients. As a secondary endpoint, it will be analyzed through a Raman spectroscope whether the changes induced by the product will be able to modify the local skin oxidative-reductive picture through spectroscopic analysis on the skin of dermal carotenoids.

Study Procedures: Participants will undergo the following tests :

t0: instrumental evaluation, initial parameter recording, administration of clinical evaluation tests, photographic iconography, and first injection of Karisma.

t1: first check after 15 days, instrumental evaluation, administration of clinical evaluation tests, photographic iconography.

t2: second check 30 days after the first injection of Karisma, instrumental evaluation, administration of clinical evaluation tests, photographic iconography, second injection of Karisma.

t3: third check 60 days after the first injection of Karisma, instrumental evaluation, administration of clinical evaluation tests, photographic iconography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Manifestations

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

regenerative medicine skin ageing collagen production filler Hyaluronic acid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Karisma

Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age range 20-65 years old
* skin ageing evidences from mild to severe

Exclusion Criteria

* not affected by oncological diseases
* rheumatological diseases
* allergic diseases
* chronic inflammatory diseases (including dermatitis, psoriasis, etc.). Patients should not have;
* metabolic diseases
* cardiovascular diseases,
* should not have received other injections of hyaluronic acid or similar substances for at least 6 months before the start of treatment,
* should not take systemic drugs during the study
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Novi Sad, Faculty of Sport and Physical Education

OTHER

Sponsor Role collaborator

Patrizia Proia, University of Palermo

UNKNOWN

Sponsor Role collaborator

Filippo Castrogiovanni, Taumedika s.r.l

UNKNOWN

Sponsor Role collaborator

Antonino De Pasquale, University of Catania

UNKNOWN

Sponsor Role collaborator

Luigi Di Rosa, University of Palermo

UNKNOWN

Sponsor Role collaborator

Sara Baldassano, University of Palermo

UNKNOWN

Sponsor Role collaborator

University of Palermo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sonya Vasto

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NabBio

Palermo, PA, Italy

Site Status

University of Novi Sad, Serbia

Novi Sad, , Serbia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy Serbia

References

Explore related publications, articles, or registry entries linked to this study.

Haddad S, Galadari H, Patil A, Goldust M, Al Salam S, Guida S. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022 Oct;61(10):1284-1288. doi: 10.1111/ijd.16229. Epub 2022 Apr 29.

Reference Type BACKGROUND
PMID: 35486036 (View on PubMed)

Fallacara A, Manfredini S, Durini E, Vertuani S. Erratum: Hyaluronic Acid Fillers in Soft Tissue Regeneration. Facial Plast Surg. 2017 Apr;33(2):244. doi: 10.1055/s-0037-1601851. Epub 2017 Apr 7. No abstract available.

Reference Type BACKGROUND
PMID: 28388806 (View on PubMed)

Kapoor KM, Saputra DI, Porter CE, Colucci L, Stone C, Brenninkmeijer EEA, Sloane J, Sayed K, Winaya KK, Bertossi D. Treating Aging Changes of Facial Anatomical Layers with Hyaluronic Acid Fillers. Clin Cosmet Investig Dermatol. 2021 Aug 26;14:1105-1118. doi: 10.2147/CCID.S294812. eCollection 2021.

Reference Type BACKGROUND
PMID: 34471372 (View on PubMed)

Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, Khan S, Sohail M, Ramli NA, Thu HE, Hussain Z. Hyaluronic acid, a promising skin rejuvenating biomedicine: A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j.ijbiomac.2018.09.188. Epub 2018 Oct 1.

Reference Type BACKGROUND
PMID: 30287361 (View on PubMed)

Vasvani S, Kulkarni P, Rawtani D. Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies. Int J Biol Macromol. 2020 May 15;151:1012-1029. doi: 10.1016/j.ijbiomac.2019.11.066. Epub 2019 Nov 9.

Reference Type BACKGROUND
PMID: 31715233 (View on PubMed)

Iaconisi GN, Lunetti P, Gallo N, Cappello AR, Fiermonte G, Dolce V, Capobianco L. Hyaluronic Acid: A Powerful Biomolecule with Wide-Ranging Applications-A Comprehensive Review. Int J Mol Sci. 2023 Jun 18;24(12):10296. doi: 10.3390/ijms241210296.

Reference Type BACKGROUND
PMID: 37373443 (View on PubMed)

Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol. 2011 Jan 1;3(1):a004978. doi: 10.1101/cshperspect.a004978.

Reference Type BACKGROUND
PMID: 21421911 (View on PubMed)

Avila Rodriguez MI, Rodriguez Barroso LG, Sanchez ML. Collagen: A review on its sources and potential cosmetic applications. J Cosmet Dermatol. 2018 Feb;17(1):20-26. doi: 10.1111/jocd.12450. Epub 2017 Nov 16.

Reference Type BACKGROUND
PMID: 29144022 (View on PubMed)

Chattopadhyay S, Raines RT. Review collagen-based biomaterials for wound healing. Biopolymers. 2014 Aug;101(8):821-33. doi: 10.1002/bip.22486.

Reference Type BACKGROUND
PMID: 24633807 (View on PubMed)

Rapaport MJ, Salit R, Rivkin L. Collagen injections for aging skin lines (wrinkles). J Am Acad Dermatol. 1984 Aug;11(2 Pt 1):250-2. doi: 10.1016/s0190-9622(84)70159-9.

Reference Type BACKGROUND
PMID: 6480926 (View on PubMed)

Lucey P, Goldberg DJ. Complications of collagen fillers. Facial Plast Surg. 2014 Dec;30(6):615-22. doi: 10.1055/s-0034-1396904. Epub 2014 Dec 23.

Reference Type BACKGROUND
PMID: 25536127 (View on PubMed)

Cui Y, Wang F, Voorhees JJ, Fisher GJ. Rejuvenation of Aged Human Skin by Injection of Cross-linked Hyaluronic Acid. Plast Reconstr Surg. 2021 Jan 1;147(1S-2):43S-49S. doi: 10.1097/PRS.0000000000007620.

Reference Type BACKGROUND
PMID: 33347074 (View on PubMed)

Wells JM, Gaggar A, Blalock JE. MMP generated matrikines. Matrix Biol. 2015 May-Jul;44-46:122-9. doi: 10.1016/j.matbio.2015.01.016. Epub 2015 Jan 28.

Reference Type BACKGROUND
PMID: 25636538 (View on PubMed)

Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the regulation of extracellular matrix degradation. Biochimie. 2005 Mar-Apr;87(3-4):353-60. doi: 10.1016/j.biochi.2004.10.006.

Reference Type BACKGROUND
PMID: 15781322 (View on PubMed)

Wu GT, Kam J, Bloom JD. Hyaluronic Acid Basics and Rheology. Facial Plast Surg Clin North Am. 2022 Aug;30(3):301-308. doi: 10.1016/j.fsc.2022.03.004.

Reference Type BACKGROUND
PMID: 35934432 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

49-10-02-2023-1

Identifier Type: -

Identifier Source: org_study_id